Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies.
Fanotto V, Rossini D, Casagrande M, Bergamo F, Spagnoletti A, Santini D, Antoniotti C, Cupini S, Daniel F, Nasca V, Vetere G, Zaniboni A, Borelli B, Carullo M, Conca V, Passardi A, Tamburini E, Masi G, Pella N, Cremolini C. Fanotto V, et al. Among authors: conca v. Cancers (Basel). 2023 Nov 16;15(22):5451. doi: 10.3390/cancers15225451. Cancers (Basel). 2023. PMID: 38001711 Free PMC article.
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.
Lombardi P, Rossini D, Crespi V, Germani MM, Bergamo F, Pietrantonio F, Santini D, Allegrini G, Daniel F, Pagani F, Antoniotti C, Zaniboni A, Conca V, Latiano TP, Boccaccino A, Passardi A, Tamburini E, Masi G, Di Maio M, Cremolini C. Lombardi P, et al. Among authors: conca v. Cancer Treat Rev. 2022 Feb;103:102326. doi: 10.1016/j.ctrv.2021.102326. Epub 2021 Dec 23. Cancer Treat Rev. 2022. PMID: 35016085
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.
Antoniotti C, Germani MM, Rossini D, Lonardi S, Pietrantonio F, Santini D, Marmorino F, Allegrini G, Daniel F, Raimondi A, Borelli B, Zaniboni A, Conca V, Abraham J, Spetzler D, Maiello E, Boccaccino A, Passardi A, Giordano M, Tamburini E, Korn MW, Masi G, Cremolini C. Antoniotti C, et al. Among authors: conca v. Eur J Cancer. 2022 May;167:23-31. doi: 10.1016/j.ejca.2022.02.031. Epub 2022 Mar 30. Eur J Cancer. 2022. PMID: 35366570
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
Rossini D, Germani MM, Lonardi S, Pietrantonio F, Dell'Aquila E, Borelli B, Allegrini G, Maddalena G, Randon G, Marmorino F, Zaniboni A, Buonadonna A, Boccaccino A, Conca V, Antoniotti C, Passardi A, Masi G, Cremolini C. Rossini D, et al. Among authors: conca v. Eur J Cancer. 2022 Jul;170:64-72. doi: 10.1016/j.ejca.2022.04.019. Epub 2022 May 17. Eur J Cancer. 2022. PMID: 35594613
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study.
Moretto R, Giordano M, Poma AM, Passardi A, Boccaccino A, Pietrantonio F, Tomasello G, Aprile G, Lonardi S, Conca V, Granetto C, Frassoldati A, Clavarezza M, Bertolini AS, Germani MM, Ugolini C, Fontanini G, Masi G, Falcone A, Cremolini C. Moretto R, et al. Among authors: conca v. Eur J Cancer. 2021 Aug;153:16-26. doi: 10.1016/j.ejca.2021.04.039. Epub 2021 Jun 12. Eur J Cancer. 2021. PMID: 34126333
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
Moretto R, Rossini D, Conca V, Lonardi S, Rasola C, Antoniotti C, Santini D, Marmorino F, Tomasello G, Borelli B, Caponnetto S, Zucchelli G, Zaniboni A, Ambrosini M, Buonadonna A, Fanchini L, Cupini S, Masi G, Falcone A, Cremolini C. Moretto R, et al. Among authors: conca v. Br J Cancer. 2021 Sep;125(6):839-845. doi: 10.1038/s41416-021-01483-x. Epub 2021 Jul 12. Br J Cancer. 2021. PMID: 34253871 Free PMC article.
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.
Moretto R, Rossini D, Capone I, Boccaccino A, Perrone F, Tamborini E, Masi G, Antoniotti C, Marmorino F, Conca V, Borelli B, Martignetti A, Pecora I, Simionato F, Cupini S, Ambrosini M, Manca P, Pietrantonio F, Falcone A, Cremolini C. Moretto R, et al. Among authors: conca v. Clin Colorectal Cancer. 2021 Dec;20(4):314-317. doi: 10.1016/j.clcc.2021.07.001. Epub 2021 Jul 10. Clin Colorectal Cancer. 2021. PMID: 34364814 Clinical Trial.
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
Antoniotti C, Korn WM, Marmorino F, Rossini D, Lonardi S, Masi G, Randon G, Conca V, Boccaccino A, Tomasello G, Passardi A, Swensen J, Ugolini C, Oberley M, Tamburini E, Casagrande M, Domenyuk V, Fontanini G, Giordano M, Abraham J, Spetzler D, Falcone A, Lenz HJ, Cremolini C. Antoniotti C, et al. Among authors: conca v. Eur J Cancer. 2021 Sep;155:73-84. doi: 10.1016/j.ejca.2021.06.037. Epub 2021 Aug 5. Eur J Cancer. 2021. PMID: 34365081
61 results